109 related articles for article (PubMed ID: 3806619)
1. Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism.
Kwon CH; Borch RF; Engel J; Niemeyer U
J Med Chem; 1987 Feb; 30(2):395-9. PubMed ID: 3806619
[TBL] [Abstract][Full Text] [Related]
2. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.
Niemeyer U; Engel J; Scheffler G; Molge K; Sauerbier D; Weigert W
Invest New Drugs; 1984; 2(2):133-9. PubMed ID: 6469506
[TBL] [Abstract][Full Text] [Related]
3. Spectroscopic detection of iminocyclophosphamide and its possible role in cyclophosphamide metabolism.
Kwon CH; Kirk MC; Struck RF; Borch RF
J Med Chem; 1987 Jun; 30(6):1110-4. PubMed ID: 3585908
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of activation of 4-hydroxycyclophosphamide.
Borch RF; Millard JA
J Med Chem; 1987 Feb; 30(2):427-31. PubMed ID: 3806624
[TBL] [Abstract][Full Text] [Related]
5. Base-catalyzed hydrolysis of 4-hydroperoxycyclophosphamide: evidence for iminocyclophosphamide as an intermediate.
Borch RF; Getman KM
J Med Chem; 1984 Apr; 27(4):485-90. PubMed ID: 6708050
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies.
Sonawat HM; Leibfritz D; Engel J; Hilgard P
Biochim Biophys Acta; 1990 Apr; 1052(1):36-41. PubMed ID: 2322593
[TBL] [Abstract][Full Text] [Related]
7. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways.
Zon G; Ludeman SM; Brandt JA; Boyd VL; Ozkan G; Egan W; Shao KL
J Med Chem; 1984 Apr; 27(4):466-85. PubMed ID: 6708049
[TBL] [Abstract][Full Text] [Related]
8. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
9. In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution.
Borch RF; Hoye TR; Swanson TA
J Med Chem; 1984 Apr; 27(4):490-4. PubMed ID: 6708051
[TBL] [Abstract][Full Text] [Related]
10. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. 2. Direct observation, characterization, and reactivity studies of iminocyclophosphamide and related species.
Boyd VL; Summers MF; Ludeman SM; Egan W; Zon G; Regan JB
J Med Chem; 1987 Feb; 30(2):366-74. PubMed ID: 3806617
[TBL] [Abstract][Full Text] [Related]
11. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
12. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues.
Kwon CH; Borch RF
J Med Chem; 1989 Jul; 32(7):1491-6. PubMed ID: 2738883
[TBL] [Abstract][Full Text] [Related]
13. Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.
Wagner T; Zink M; Schwieder G
J Cancer Res Clin Oncol; 1987; 113(2):160-5. PubMed ID: 3104347
[TBL] [Abstract][Full Text] [Related]
14. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide.
Davidoff AN; Mendelow BV
Exp Hematol; 1993 Jul; 21(7):922-7. PubMed ID: 8319782
[TBL] [Abstract][Full Text] [Related]
15. The chemistry of the metabolites of cyclophosphamide.
Ludeman SM
Curr Pharm Des; 1999 Aug; 5(8):627-43. PubMed ID: 10469895
[TBL] [Abstract][Full Text] [Related]
16. N3-methyl-mafosfamide as a chemically stable, alternative prodrug of mafosfamide.
Moon KY; Kwon CH
Bioorg Med Chem Lett; 1998 Jul; 8(13):1673-8. PubMed ID: 9873412
[TBL] [Abstract][Full Text] [Related]
17. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluoro- and 5-chlorocyclophosphamide: synthesis, metabolism, and antitumor activity of the cis and trans isomers.
Foster AB; Jarman M; Kinas RW; van Maanen JM; Taylor GN; Gaston JL; Parkin A; Richardson AC
J Med Chem; 1981 Dec; 24(12):1399-403. PubMed ID: 7310816
[TBL] [Abstract][Full Text] [Related]
19. Intracavitary chemotherapy with activated cyclophosphamides and simultaneous systemic detoxification with protector thiols in Sarcoma 180 ascites tumor.
Wagner T; Mittendorff F; Walter E
Cancer Res; 1986 May; 46(5):2214-9. PubMed ID: 3697966
[TBL] [Abstract][Full Text] [Related]
20. Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.
Draeger J; Peter G; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):355-9. PubMed ID: 1277211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
